IMMvention Therapeutix works on first-in-class Bach1 inhibitors with transformative potential as oral therapy for patients with sickle cell disease (SCD) and beyond.

IMMvention's mission is to create a globally accessible therapy, benefiting patients with limited or no access to gene therapies. Currently in preclinical stage, IMM-4800 has exceptional drug …

IMMvention is powered by its experienced team with deep expertise in drug discovery and development across multiple therapeutic areas

Currently in preclinical development, IMMvention’s orally dosed BACH1 inhibitors have the potential to increase fetal hemoglobin, which is believed to ameliorate SCD disease pathology. …

We'd love to hear from you! Whether you have questions, feedback, or need assistance, our team is here to help—just reach out to us through the form below. Thank you for connecting with us!

Stay informed and inspired with our news + blog, where we share the latest news, expert insights, and valuable tips across various topics. From industry trends to practical advice, our blog is …

IMMvention

First-in-class Bach1 inhibitors with transformative potential as oral therapy in sickle cell disease and beyond.